Ginkgo Bioworks Holdings, Inc.
DNA
$10.33
-$0.43-4.00%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.21% | 13.76% | -9.71% | -30.81% | -43.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.21% | 13.76% | -9.71% | -30.81% | -43.45% |
| Cost of Revenue | 33.02% | 16.07% | -17.51% | -46.48% | -61.76% |
| Gross Profit | 23.29% | 13.20% | -7.57% | -25.68% | -35.88% |
| SG&A Expenses | -30.70% | -28.59% | -30.92% | -33.18% | -61.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 312.85% | 181.87% | 37.50% | 37.50% | 37.50% |
| Total Operating Expenses | -38.89% | -29.83% | -27.82% | -30.79% | -45.11% |
| Operating Income | 56.32% | 43.04% | 34.07% | 30.79% | 45.54% |
| Income Before Tax | 64.79% | 44.67% | 38.68% | 25.02% | 27.38% |
| Income Tax Expenses | -89,600.00% | -245.90% | -574.65% | 97.60% | 100.01% |
| Earnings from Continuing Operations | 64.89% | 44.71% | 38.73% | 23.77% | 26.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.89% | 44.71% | 38.73% | 23.98% | 26.65% |
| EBIT | 56.32% | 43.04% | 34.07% | 30.79% | 45.54% |
| EBITDA | 62.18% | 47.65% | 36.58% | 31.95% | 48.06% |
| EPS Basic | 67.53% | 48.34% | 42.17% | 27.78% | 35.80% |
| Normalized Basic EPS | 60.20% | 47.59% | 38.18% | 32.66% | 55.26% |
| EPS Diluted | 67.54% | 48.38% | 42.20% | 28.05% | 35.95% |
| Normalized Diluted EPS | 60.19% | 47.58% | 38.17% | 32.65% | 55.26% |
| Average Basic Shares Outstanding | 7.74% | 7.63% | 6.74% | 6.17% | 8.91% |
| Average Diluted Shares Outstanding | 7.72% | 7.61% | 6.72% | 6.16% | 8.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |